grant
Bladder Cancer Program
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY2025Adjuvant ChemotherapyAdjuvant Drug TherapyAdjuvant StudyAdjuvant TrialsAreaB7-H1Bladder CancerBladder Urothelial CarcinomaBladder removalCD274Cancer CauseCancer EtiologyCancersCessation of lifeClinicalCystectomyDeathDisease-Free SurvivalDoseEvent-Free SurvivalImmune mediated therapyImmunologically Directed TherapyImmunotherapyInduction TherapyIntentionKeytrudaMalignant Bladder NeoplasmMalignant NeoplasmsMalignant TumorMalignant Tumor of the BladderMalignant neoplasm of urinary bladderModalityMuscleMuscle TissueNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentPD-L1PDL-1PathologicPatientsPhase 3 Clinical TrialsPhase III Clinical TrialsPopulationPrincipal InvestigatorProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1RandomizedReportingResearchTestingTransitional CarcinomaTransitional Cell CarcinomaUnited StatesUrinary Bladder CancerUrinary Bladder Malignant TumorUrinary Bladder Transitional Cell CarcinomaUrothelial CarcinomaWomanadjuvant protocolbladder transitional cell carcinomahigh riskimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimproved outcomeinduction therapiesmalignancymenmuscularneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypembrolizumabphase 3 trialphase III protocolphase III trialprogrammed cell death ligand 1programmed cell death protein ligand 1programsprotein death-ligand 1randomisationrandomizationrandomly assignedresponseurinary bladder urothelial carcinoma
Description preview
I initiated a phase 3 clinical trial of adjuvant pembrolizumab post-cystectomy in patients with high-risk muscle-invasive urothelial carcinoma of the bladder and upper tract. I am the principal investigator on this Alliance/NCI-sponsored study. In this phase 3 trial, we randomly assigned patients, in a 1:1 ratio, to receive pembrolizumab at a dose…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click